23andMe Investor Presentation Deck

We Have Generated a Research and Development Pipeline Covering Multiple Therapeutic Areas Immuno-oncology GSK'608 (CD96) EARLY-STAGE THERAPEUTIC AREAS (multiple programs in each area) Immuno-oncology Immunology 23ME'610 (CD200R1) Cardiovascular/ Metabolic Neurology Discovery Preclinical Phase 1 140+ programs in the combined therapeutic areas. Programs include collaborated, 100% owned and royalty interest targets. Note: As of March 31, 2021 40+ programs¹ gsk 23andMe Phase 2 Copyright © 2022 23and Me, Inc. Next Milestone Phase 1 Data Phase 1 Data 23andMe 36

View entire presentation